GGGema Gonzalez-Rubio

Gema Gonzalez-Rubio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gema Gonzalez-Rubio has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel nirmatrelvir-resistance mutations in SARS-CoV-2 Mpro using a yeast screening platform

    by Óscar Barbero-Úriz, Gema González-Rubio, Marta Valenti, María Molina, Víctor J. Cid, Teresa Fernández-Acero

  • Open Access

    Cholesterol constrains pore formation by mammalian gasdermins

    by Yisha Liang, Isabella R. Evavold, Sepideh Parvanian, Makiko Hayashi, Emerson Glassey, Gema González-Rubio, Inga M. Spannaus, Victoria De Andrade, Benjamin L. Allsup, Fan Fei, et al.

    Pyroptosis is a lytic form of cell death executed by gasdermin pores. Through a CRISPR screen to uncover macrophage genes required for gasdermin D (GSDMD) pore activity, we identify the endosome adaptor Rabgef1 as a positive regulator of pore formation. Rabgef1 deficiency preserves NT-GSDMD membrane binding but prevents NT-GSDMD oligomerization and lytic death. Mechanistic analyses revealed that Rabgef1 deficiency is associated with an overabundance of cholesterol in the plasma membrane. Cholesterol depletion or redistribution through multiple approaches restores GSDMD oligomerization and pyroptosis. The Rabgef1-mediated control of membrane cholesterol and pore formation was found to be a general regulator of the gasdermin family. In cancer cells, organoids, and tumors, cholesterol reduction sensitizes resistant cells to GSDME pyroptosis driven by synthetic mRNAs, chemogenetic induction, and chemotherapy treatment. These results establish membrane cholesterol content as an endogenous checkpoint for gasdermin-mediated pyroptotic cell death during the execution phase, with implications for metabolic disease and cancer immunotherapy.

  • Open Access

    Role of the yeast Cell Wall Integrity pathway in the response to clotrimazole: a phosphoproteomic analysis

    by Ángela Sellers-Moya, Gema Gonzalez-Rubio, Graciela Alonso, Beatriz Lavilla-García, Victor J. Cid, Luca Takacs, Frank Uhlmann, María Molina, Humberto Martín

    Phosphorylation is a highly prevalent, dynamic, and effective mechanism of signal transduction, but the phosphorylation events underlying the cellular response to plasma membrane and cell wall stress remain poorly understood. In this study, we performed time-resolved phosphoproteomic analysis of Saccharomyces cerevisiae wild-type and mutant cells lacking the MAPK Slt2 to characterize the yeast response to the widely used antifungal agent clotrimazole and to define the contribution of the Cell Wall Integrity pathway to this response. Slt2-dependent phosphotargets included proteins associated with known functions in gene expression, cytoskeletal organization, and the oxidative stress response. Additionally, we identified previously unknown targets with roles in protein secretion and cell cycle regulation, including Sdh8, Sec65, and Yox1, which we confirmed using in vitro kinase assays. We further confirmed the G1/S regulator Yox as an in vivo Slt2 target of the Cell Wall Integrity response. Overall, our study provides a comprehensive overview of the phosphorylation response to cell wall stress and identifies previously unexplored cellular pathways that form part of this response.

  • Open Access

    Novel Nirmatrelvir-Resistance Mutations in SARS-CoV-2 3CLpro Using a Yeast Screening Platform

    by Teresa Fernandez-Acero, Óscar Barbero-Úriz, Gema Gonzalez-Rubio, Marta Valenti, María Molina, Victor J. Cid

    SARS-CoV-2 is a positive-sense single-stranded RNA virus of the Coronaviridae family. Emerging coronaviruses posing pandemic risk and the swift appearance of new antigenic variants of circulating SARS-CoV-2 urge the need for new and diverse effective treatments. The most outstanding targets to inhibit viral replication are its cysteine-proteases, 3CLpro and PLpro, which are essential for virus life cycle. Here, we investigated the functional consequences of heterologously expressed SARS-CoV-2 proteases in the eukaryotic model Saccharomyces cerevisiae. Both overproduced 3CLpro and PLpro caused yeast growth inhibition. This phenotype was dependent on their protease activities, since it was abrogated by the expression of catalytically inactive mutants or counteracted by the treatment with known protease inhibitors. 3CLpro reproduced in yeast the proteolytic cleavage of the pore-forming protein Gasdermin D, previously described in human cell lines. We generated a yeast-based screening platform to detect mutations in 3CLpro conferring resistance to inhibitors. To this end, we evaluated the behaviour of the purported resistant mutant, 3CLproE166V, and found a resistant pattern to nirmatrelvir. Taking advantage of this model, we performed a random mutagenesis screen to isolate nirmatrelvir-resistant mutations in 3CLpro. Our screening identified nine clones. Five harbored previously described mutations, either identical (A260V) or involving alternative substitutions (G15N/F159I, G23E/D33N/R60K, C128R/R188K, S139I). Importantly, our study also revealed four novel residues that have not yet been associated with nirmatrelvir resistance (K88R, L220M, Y209F, L262M). In sum, we report a suitable model to screen compounds in search of new 3CLpro and PLpro inhibitors and to predict mutations associated to drug resistance.